William D. Waddill Sells 4,000 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Stock

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Director William D. Waddill sold 4,000 shares of the company’s stock in a transaction on Monday, March 17th. The stock was sold at an average price of $54.25, for a total value of $217,000.00. Following the completion of the sale, the director now directly owns 13,130 shares in the company, valued at approximately $712,302.50. The trade was a 23.35 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Protagonist Therapeutics Price Performance

Shares of NASDAQ:PTGX opened at $53.05 on Friday. The company has a market cap of $3.26 billion, a P/E ratio of 19.94 and a beta of 2.34. Protagonist Therapeutics, Inc. has a 1 year low of $24.22 and a 1 year high of $60.60. The stock’s fifty day moving average price is $40.89 and its 200-day moving average price is $42.55.

Protagonist Therapeutics (NASDAQ:PTGX) last announced its quarterly earnings results on Friday, February 21st. The company reported $1.98 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.09) by $2.07. The firm had revenue of $170.64 million for the quarter, compared to the consensus estimate of $56.65 million. Protagonist Therapeutics had a return on equity of 34.68% and a net margin of 52.76%. On average, sell-side analysts anticipate that Protagonist Therapeutics, Inc. will post 2.43 earnings per share for the current year.

Analyst Ratings Changes

PTGX has been the topic of several recent research reports. Truist Financial upped their price target on Protagonist Therapeutics from $60.00 to $76.00 and gave the stock a “buy” rating in a research note on Tuesday, March 11th. JMP Securities reissued a “market outperform” rating and issued a $58.00 target price on shares of Protagonist Therapeutics in a report on Friday, February 7th. StockNews.com downgraded Protagonist Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, December 10th. BMO Capital Markets boosted their target price on Protagonist Therapeutics from $62.00 to $72.00 and gave the stock an “outperform” rating in a report on Tuesday, March 11th. Finally, JPMorgan Chase & Co. boosted their target price on Protagonist Therapeutics from $53.00 to $57.00 and gave the stock an “overweight” rating in a report on Tuesday, March 4th. Two research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $62.56.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of PTGX. FNY Investment Advisers LLC purchased a new stake in Protagonist Therapeutics during the fourth quarter valued at $38,000. GF Fund Management CO. LTD. purchased a new stake in Protagonist Therapeutics during the fourth quarter valued at $48,000. Harvest Fund Management Co. Ltd purchased a new stake in Protagonist Therapeutics during the third quarter valued at $69,000. Covestor Ltd increased its position in Protagonist Therapeutics by 5,200.0% during the fourth quarter. Covestor Ltd now owns 1,643 shares of the company’s stock valued at $63,000 after acquiring an additional 1,612 shares during the last quarter. Finally, KBC Group NV increased its position in Protagonist Therapeutics by 54.4% during the fourth quarter. KBC Group NV now owns 2,093 shares of the company’s stock valued at $81,000 after acquiring an additional 737 shares during the last quarter. 98.63% of the stock is owned by institutional investors.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.